

Omnitech Systems announces

an innovative patented procedure and device that prevents the risks of the long-term complications associated with over 800,000 Global Endometrial Ablation (GEA) procedures performed annually.

- Risks:**
- **Endometrial Cancer (Delayed diagnosis)**
 - **Premature Metastatic Disease (Cancer)**
 - **Hysterectomy (>29% after 5 years)**
 - **Cornual Hematometra (Pain)**
 - **Post Ablation Tubal Sterilization Syndrome (Pain)**
 - **Amenorrhea (Cessation of periods)**
 - **Difficulty in performing Endometrial Biopsy**

A note from the president:

Since 1995 Omnitech Systems, Inc. has been involved in the design, development and manufacture of innovative medical devices for Urology and Gynecology. As a supplier of electro-surgical devices to numerous major medical device companies, it is not unusual to find myself in the O.R. to observe and consult with physicians on procedures and to quantify our product's performance standards. One such meeting occurred in 2000 with Dr. Arthur McCausland, in Sacramento California. I will never forget that meeting where the passions of a pioneer medical professional and the imagination of a medical device inventor combined in such a way that the treatment of menorrhagia will be advanced as never before. The result of that collaboration was the eventual issuance of a patent for a procedure and device to perform Partial Endometrial Ablations (PEA) which prevents intrauterine scarring. The impact for patients is that long-term complications of Global Endometrial Ablation (GEA) will diminish as PEA becomes the Gold Standard for the treatment of menorrhagia.

A key component of the mission statement of Omnitech Systems focuses on our passion of being a 'Premier Medical Device Manufacturer'. The development of the Partial Endometrial Ablation device (PEA) is certainly an important element of that internal goal; but more importantly, opens a new avenue for us in the field of Women's Health.

Our immediate goal is to continue the developmental process of the PEA while working toward near-term commercialization of the device. This is a major endeavor for us and will require extraordinary commitments of time and resources. Both the medical and financial impacts of the PEA appear limitless, and we are prepared to make the necessary commitments to realize each one.

While our R & D department has several other patentable devices under development, our senior management team sees the PEA as a tipping point for our company. We are currently looking at several options to bring the PEA to market. Those options include:

- Self-funding the project and marketing the PEA through our sister company, UroGyn Medical. UroGyn has working relationships with a network of distributors that offer high-quality devices that are complimentary to the PEA.
- Forming an exclusive partnership agreement with a major Women's Health company. To secure the funding necessary to complete the developmental, trial and commercialization process we are prepared to share the PEA with a single partnering company.
- We are prepared to consider offering Omnitech Systems in a merger or an acquisition with another company.
- Direct investment from private investors. Omnitech Systems, Inc. is willing to discuss capital investment as a consideration of percentage ownership. This with no rights of voting or active management.
- While Omnitech Systems, Inc. is a privately held company, we are not ruling out the possibility of raising significant capital by means of an Initial Public Offering of company stock.

Our dedication to the PEA and its impact on Women's Health is steadfast and we are planning to introduce a working proto-type at the American Association of Gynecologic Laparoscopists (AAGL) 37th Global Congress at the Las Vegas Paris Hotel October 28 – November 1, 2008.

Gregg A. VanDusseldorp Sr.

Gregg A. VanDusseldorp Sr.
President
Omnitech Systems, Inc.